Manufacturer
GlaxoSmithKline Manufacturing S.p.A
Contents
Ceftazidime pentahydrate
Indication
Severe infections & resp tract, ENT, urinary tract & GIT, biliary & abdominal infections, skin & soft tissue infections, bone & joint infections & infections associated w/ haemo- & peritoneal dialysis w/ continuous ambulatory peritoneal dialysis (CAPD).
Instruction
Adult 1-6 g daily IV or IM inj in 2 or 3 divided doses. Urinary tract & less severe infections 500 mg or 1 g every 12 hr. Most infections 1 g every 8 hr or 2 g every 12 hr. Very severe infections in immunocompromised patient including those w/ neutropenia 2 g every 8 or 12 hr or 3 g every 12 hr. Fibrocystic adult w/ pseudomonal lung infections 100-150 mg/kg daily in 3 divided doses. Infant & childn >2 mth 30-100 mg/kg daily in 2 or 3 divided doses. Immunocompromised or fibrocystic childn or childn w/ meningitis Up to 150 mg/kg daily in 3 divided doses. Max: 6 g daily. Neonate 0-2 mth 25-60 mg/kg daily in 2 divided doses. Elderly Max: 3 g daily. Renal impairment CrCl 31-50 mL/min 1 g every 12 hr, 16-30 mL/min 1 g every 24 hr, 6-15 mL/min 0.5 g every 24 hr, <5 mL/min 0.5 g every 48 hr. Renal failure patient on continuous arteriovenous haemodialysis or high-flux haemofiltration 1 g daily as a single dose or in divided doses.
Drug interaction
Affected renal function w/ nephrotoxic drugs. Lowered oestrogen reabsorption & reduced efficacy of combined OC. Possible antagonism w/ chloramphenicol.
Malaysia
